Native name | 大江生醫股份有限公司 |
|---|---|
| Company type | Public (Taiwan OTC) |
| TWSE: 8436[1] | |
| Industry | Biotechnology; health & personal care manufacturing (CDMO/ODM) |
| Founded | August 1, 1980 (1980-08-01) |
| Founder | Ta Chiang International Co., Ltd. (original corporate entity) |
| Headquarters | 8F, No. 187, Gangqian Road, Neihu District, , |
Key people | Lin Yong-Hsiang (林詠翔) (Chairman & CEO) |
| Products | Functional beverages, dietary supplements, probiotics, collagen, skincare/beauty products (CDMO/ODM) |
| Revenue | (see financials section) |
Number of employees | ~884 (group-wide, 2021 est.) |
| Website | www.tci-bio.com |
TCI Co., Ltd. (Chinese: 大江生醫股份有限公司) is a Taiwanese contract development and manufacturing organization (CDMO) specialising in the research, development and production of functional beverages, dietary supplements and skincare products.[2] Headquartered in the Neihu Technology Park in Taipei, TCI evolved from an original trading company founded in 1980 into a CDMO group serving clients across Asia, Europe and North America, and is publicly traded on Taiwan's over-the-counter market under the code 8436.[3]
History
The corporate origins trace back to 1980, when the predecessor trading company (Ta Chiang International) was established. In the late 1990s the group created a biomedical division and moved progressively into health-care product development and manufacturing.[4]
In 2011 the company transitioned its business model from an ODM (original design manufacturer) to a CDMO (contract development and manufacturing organisation), emphasising integrated bioscience design, proprietary ingredient development and turnkey manufacturing services for clients seeking private-label and brand products.[5]
The firm went public on Taiwan’s OTC market in 2013 (listing date 12 September 2013) with stock code 8436, accelerating capital access for factory expansion, R&D laboratories and overseas business development.[6]
Since the 2010s TCI has expanded into multiple subsidiaries and business lines (including genetic testing and digital health services), pursued international client partnerships, and invested in laboratory and production capacity—reporting a group workforce in the high hundreds and multiple manufacturing sites and laboratories by the early 2020s.[7]
Operations and products
TCI provides end-to-end services for the nutraceutical and cosmetic sectors: market analysis and concept design, ingredient sourcing and proprietary raw material development (IBD—Integrated Bioscience Design), formulation R&D, stability and safety testing, pilot production, and full-scale manufacturing for capsules, softgels, liquids, powders, and cosmetic formulations. The company markets private-label products under group consumer channels as well as acting as a CDMO for domestic and international brands.[8]
Subsidiaries and affiliated brands include genetic testing (TCI GENE) and consumer retail channels (TCI Living), reflecting a diversification strategy across upstream R&D and downstream retail.[9]
Public listing, financials and governance
TCI is listed on Taiwan’s OTC market (stock code 8436). Regulatory and investor pages report the company’s registration details, public offering timeline (public offering 25 August 2011; OTC listing 12 September 2013), paid-in capital and disclosure contacts. Quarterly and annual reports are published on the company’s investor relations pages.[10][11]
Recognition and sustainability
TCI has publicly promoted sustainability initiatives and in recent years participated in corporate sustainability networks. Industry reporting and chamber notices noted TCI’s membership in RE100 initiatives or climate/sustainability collaborations, positioning the company among early adopters in Taiwan’s biotech/manufacturing sector to commit to renewable energy targets and net-zero ambitions.[12]
Contemporary developments and strategy
Throughout the 2020s TCI pursued an acquisition and expansion phase, increasing capacity for CDMO services, establishing additional labs, and extending product portfolios into probiotics, collagen, functional drinks and clinical-grade ingredients.[13] The company emphasizes integrated R&D, regulatory compliance for international markets, and sustainability in manufacturing operations.[14]
Criticism and market challenges
As with many contract manufacturers in the nutraceutical and cosmetic sectors, TCI faces sector-wide pressures including regulatory compliance across multiple jurisdictions, supply-chain volatility (raw material sourcing), increasing competition from lower-cost regional producers, and the need to demonstrate product efficacy and safety through independent clinical evidence.[15] Publicly available sources emphasize the company’s efforts to address these through expanded testing capabilities and R&D investment; independent media coverage and financial reports remain the primary sources for external assessment of performance and governance.[16]
See also
- Nutraceutical
- Contract development and manufacturing organization
- List of companies of Taiwan
- Daiken Bio
References
- ^ "TCI profile and market data". Yahoo Finance Taiwan. Retrieved 8 September 2025.
- ^ 謝柏宏 (2025-08-22). "大江生醫母集團三策略擴版圖". United Daily News (in Chinese (Taiwan)). Retrieved 2025-09-08.
- ^ "基本資料". TCI (大江生醫). Retrieved 8 September 2025.
- ^ "1980 (TCI timeline)". TCI (大江生醫). Retrieved 8 September 2025.
- ^ "Our Company". TCI (大江生醫). Retrieved 8 September 2025.
- ^ "上櫃資訊 (Investor Info)". TCI (大江生醫). Retrieved 8 September 2025.
- ^ "TCI Company profile (group overview)". TCI (大江生醫). Retrieved 8 September 2025.
- ^ "What Supplement Manufacturers Suit You Better?". TCI (大江生醫). Retrieved 8 September 2025.
- ^ "TCI GENE (大江基因)". Retrieved 8 September 2025.
- ^ "基本資料". TCI (大江生醫). Retrieved 8 September 2025.
- ^ "TCI (8436) company profile". EMIS. Retrieved 8 September 2025.
- ^ "LCI New Member: TCI 大江生醫". European Chamber of Commerce in Taipei (ECCT). Retrieved 8 September 2025.
- ^ 杜蕙蓉 (2019-09-11). "大江綠經濟布局效益展現 歐盟大咖親訪". China Times (in Chinese (Taiwan)). Retrieved 2025-09-08.
- ^ "TCI Company profile (group overview)". TCI (大江生醫). Retrieved 8 September 2025.
- ^ 何秀玲 (2025-08-21). "大江：加速全球輕資產布局 縮短供應鏈時程". Central News Agency (Taiwan) (in Chinese (Taiwan)). Retrieved 2025-09-08.
- ^ 陳永吉 (2025-08-21). "大江中國業績比重降至24％ 轉型走向全球市場". Liberty Times (in Chinese (Taiwan)). Retrieved 2025-09-08.
  | This article about a Taiwanese corporation or company is a stub. You can help Wikipedia by adding missing information. |
